Randomized Trial of Ceftazidime-Avibactam Vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses Per US FDA-Specified End Points
Overview
Authors
Affiliations
Background: Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections are limited. The pivotal phase III REPROVE trial evaluated the efficacy of ceftazidime-avibactam (CAZ-AVI) vs meropenem in the treatment of patients with HAP/VAP. Study results for prespecified analyses per US Food and Drug Administration-recommended trial end points are reported here.
Methods: Hospitalized adults with HAP/VAP proven or suspected to be caused by a Gram-negative pathogen were randomized 1:1 to receive CAZ-AVI or meropenem for 7 to 14 days. The primary outcome was 28-day all-cause mortality in the intent-to-treat (ITT) population. Secondary outcomes included clinical cure at test of cure (TOC) in the ITT and microbiological ITT (micro-ITT) populations, and safety and tolerability throughout the study.
Results: hundred seventy randomized patients received treatment and were included in the ITT population (CAZ-AVI, n = 436; meropenem, n = 434). CAZ-AVI was noninferior to meropenem for the primary end point (28-day all-cause mortality; ITT) based on the prespecified 10% noninferiority margin (CAZ-AVI, 9.6%; meropenem, 8.3%; difference, 1.5%; 95% confidence interval [CI], -2.4% to 5.3%) and for the clinical cure end point in the ITT population based on a prespecified -10% noninferiority margin (CAZ-AVI, 67.2%; meropenem, 69.1%; difference, -1.9%; 95% CI, -8.1% to 4.3%). Clinical cure rates at TOC for patients infected with CAZ-nonsusceptible pathogens were similar (CAZ-AVI, 75.5%; meropenem, 71.2%; micro-ITT). Safety data were consistent with established safety profiles for both agents.
Conclusions: CAZ-AVI provides an important new treatment option for HAP/VAP due to Gram-negative pathogens, including CAZ-nonsusceptible strains.
Yang W, Zhen X, Sun X, Khatiwada S, Yang D, Chen Y BMJ Open. 2024; 14(8):e086039.
PMID: 39209783 PMC: 11367305. DOI: 10.1136/bmjopen-2024-086039.
Viscardi S, Topola E, Sobieraj J, Duda-Madej A Antibiotics (Basel). 2024; 13(5).
PMID: 38786173 PMC: 11117516. DOI: 10.3390/antibiotics13050445.
Gupta N, Saseedharan S, Paliwal Y Cureus. 2024; 16(2):e54443.
PMID: 38510907 PMC: 10951683. DOI: 10.7759/cureus.54443.
Kunz Coyne A, Orzol C, Veve M, Rybak M Open Forum Infect Dis. 2023; 10(9):ofad454.
PMID: 37720698 PMC: 10500045. DOI: 10.1093/ofid/ofad454.
Dequin P, Aubron C, Faure H, Garot D, Guillot M, Hamzaoui O Ann Intensive Care. 2023; 13(1):59.
PMID: 37400647 PMC: 10317910. DOI: 10.1186/s13613-023-01155-4.